Id: acc2547
Group: 2sens
Protein: PKCzeta
Gene Symbol: PRKCZ
Protein Id: Q05513
Protein Name: KPCZ_HUMAN
PTM: ubiquitination
Site: Lys48
Site Sequence: ELCEEVRDMCRLHQQHPLTLK
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype:
Disease Cellline:
Disease Info:
Drug: HOIL-1L expression
Drug Info: -
Effect: promote
Effect Info: "High expression of HOIL - 1L leads to protein ubiquitination, promoting tumor growth."
Note: Non-conventional drugs
Score: 4.5
Pubmed(PMID): 25118570
Sentence Index:
Sentence:

Sequence & Structure:

MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQQHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGEDKSIYRRGARRWRKLYRANGHLFQAKRFNRRAYCGQCSERIWGLARQGYRCINCKLLVHKRCHGLVPLTCRKHMDSVMPSQEPPVDDKNEDADLPSEETDGIAYISSSRKHDSIKDDSEDLKPVIDGMDGIKISQGLGLQDFDLIRVIGRGSYAKVLLVRLKKNDQIYAMKVVKKELVHDDEDIDWVQTEKHVFEQASSNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKLPEEHARFYAAEICIALNFLHERGIIYRDLKLDNVLLDADGHIKLTDYGMCKEGLGPGDTTSTFCGTPNYIAPEILRGEEYGFSVDWWALGVLMFEMMAGRSPFDIITDNPDMNTEDYLFQVILEKPIRIPRFLSVKASHVLKGFLNKDPKERLGCRPQTGFSDIKSHAFFRSIDWDLLEKKQALPPFQPQITDDYGLDNFDTQFTSEPVQLTPDDEDAIKRIDQSEFEGFEYINPLLLSTEESV

No data.

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 4 - acute myeloid leukemia FDA
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 4 - neoplasm ATC
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 4 - mast-cell leukemia FDA
DailyMed
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 4 - Mastocytosis DailyMed
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 4 - systemic mastocytosis FDA
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 3 Completed acute myeloid leukemia ClinicalTrials
ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 3 Recruiting acute myeloid leukemia ClinicalTrials
ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 3 Unknown status leukemia ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Active, not recruiting myelodysplastic syndrome ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Recruiting acute myeloid leukemia ClinicalTrials
ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Withdrawn acute myeloid leukemia ClinicalTrials
ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Recruiting myelodysplastic syndrome ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Active, not recruiting acute myeloid leukemia ClinicalTrials
ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Completed acute myeloid leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Completed leukemia ClinicalTrials
PRKCZ UCN-01 Protein kinase C (PKC) inhibitor 2 Terminated lymphoma ClinicalTrials
PRKCZ SOTRASTAURIN Protein kinase C (PKC) inhibitor 2 Completed psoriasis ClinicalTrials
PRKCZ UCN-01 Protein kinase C (PKC) inhibitor 2 Completed small cell lung carcinoma ClinicalTrials
PRKCZ SOTRASTAURIN Protein kinase C (PKC) inhibitor 2 Completed ulcerative colitis ClinicalTrials
PRKCZ UCN-01 Protein kinase C (PKC) inhibitor 2 Terminated melanoma ClinicalTrials
PRKCZ UCN-01 Protein kinase C (PKC) inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Completed mast-cell leukemia ClinicalTrials
PRKCZ MIDOSTAURIN Protein kinase C (PKC) inhibitor 2 Recruiting Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive ClinicalTrials
PRKCZ SOTRASTAURIN Protein kinase C (PKC) inhibitor 2 Completed panuveitis ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 410 U Head and neck squamous cell carcinoma Phosphorylation 21281788
T 560 U Breast cancer Phosphorylation 32559461

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: